• Immutep receives A$4.6 million R&D tax incentive payment from French government
• Payment under the 'Crédit d'Impôt Recherche' (CIR) scheme, which provides 30% reimbursement for eligible R&D expenditure
• Funds will support ongoing and planned global clinical development of eftilagimod alfa and IMP761

Immutep Limited, a late-stage immunotherapy company targeting cancer and autoimmune diseases, has announced that it has received a €2,588,954 (~ A$4,567,769) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d'Impôt Recherche (CIR) scheme. The CIR is a French government tax incentive that allows French companies conducting research and development activities in Europe to be reimbursed 30% of their eligible expenditure. Immutep qualifies for the CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France. The cash payment is provided in respect of expenditure incurred on eligible R&D activities conducted in the European Union in the 2024 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government's R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia. The funds will be used to support the ongoing and planned global clinical development of Immutep's lead product candidate, eftilagimod alfa, as well as its earlier-stage product candidate, IMP761.